pristane has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, X; Fang, Y; Huang, Y; Ma, K; Qin, R; Zhou, J | 1 |
| Chen, J; He, Y; Li, H; Qiu, H; Shi, X; Song, S; Tian, W; Wen, C; Zhang, M | 1 |
| Chen, XH; Liu, H; Mo, HY; Wang, YH; Wei, SR; Wu, WJ; Xu, J; Zhu, ZZ | 1 |
3 other study(ies) available for pristane and Atherogenesis
| Article | Year |
|---|---|
Pristane attenuates atherosclerosis in Apoe
Topics: Animals; Antibodies, Neutralizing; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Female; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Plasma Cells; RNA | 2022 |
Jieduquyuziyin prescription alleviates SLE complicated by atherosclerosis via promoting cholesterol efflux and suppressing TLR9/MyD88 activation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Foam Cells; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Mice; Myeloid Differentiation Factor 88; PPAR gamma; Toll-Like Receptor 9 | 2023 |
Role of CD19
Topics: Animals; Atherosclerosis; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr; T-Lymphocytes, Regulatory; Th17 Cells | 2023 |